ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 91

A Systematic Review of Smartphone Applications for Measuring and Recording Rheumatoid Arthritis Disease Activity

Rebecca Grainger1,2, Hermaleigh Townsley3, Bonnie White4, Tobias Langlotz5 and William Taylor1,6, 1University of Otago Wellington, Wellington, New Zealand, 2Wellington Regional Rheumatology Unit, Hutt Valley District Health Board, Lower Hutt, New Zealand, 3Department of Medicine, University of Otago Wellington, Wellington, New Zealand, 4Department of Medicine, University of Otago Wellington, Wellington South, New Zealand, 5Department of Information Science, University of Otago, Dunedin, New Zealand, 6Wellington Regional Rheumatology Unit, Hutt Valley District Health Board, Wellington, New Zealand

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: MHealth, patient engagement and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2016

Title: Health Services Research - Poster I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: It is recommended that management of rheumatoid arthritis (RA) requires regular quantitative assessment of RA activity. Treat to target management could be facilitated by use of smartphone applications (“apps”) for input, storage, and transmission of validated RA disease activity measures. These data could be used by rheumatologists in clinical practice or by people with RA. However, potential users of apps must have confidence in app quality. This review assesses the functionality and quality of apps for RA disease activity monitoring by: 1) systematically identifying apps for monitoring of RA; 2) summarizing and comparing features to RA disease activity monitoring guidelines; and 3) rating app quality according to the recently developed Mobile App Rating Scale (MARS)1.

Methods: A systematic search of the Google Play and iTunes stores was conducted to identify smartphone apps designed for measurement of RA disease activity by people with RA and rheumatologists. Apps were excluded if: 1) content was for information, education, or reference only; 2) for use by clinicians only: 3) only included treatment algorithms; or 4) were not in English. Android and iOS Apps were downloaded to smartphones and features/functionality described then apps rated by two independent reviewers using the MARS. App features were compared with EULAR and ACR recommendations for monitoring of RA disease activity.

Results: The search identified 721 apps in the Google Play store and 216 in iTunes store, of which 19 unique apps met criteria for inclusion (16 Google play, 11 iTunes store, 8 both). Fourteen apps included at least one validated instrument for measurement of RA disease activity. Eleven apps allowed users to enter a joint count (homunculus n=4, number of joints n=7). Eight of these apps used the standard 28 swollen and tender joint count and functioned as composite disease activity (CDA) calculators, with no capacity to store data. Eight apps included at least one ACR/EULAR recommended RA CDA measure but only one provided the formula for calculation. Ten apps included data recording, storage, and retrieval. Only one app, Arthritis Power, included both a RA CDA measure and tracked data but this app did not include the standard 28 joint count. The median MARS score for apps was 3.41 (maximum 5). Of the five apps which scored >4/5 on the MARS rating, only one included a CDA score endorsed by ACR/EULAR but this app did not have a data tracking function.

Conclusion: No current apps for RA have functionality for entry of validated disease activity instruments, composite disease activity measures including 28 joint counts, and allow tracking of these data. Current apps are configured as calculators for rheumatologists or tracking tools for people with RA. The latter do not uniformly collect data using validated instruments. Apps which were higher quality according to the MARS collected only patient reported outcomes. Collaboration between rheumatologists, people with RA, app developers and health systems is required to develop appropriate, high quality apps for use by rheumatologists and people with RA in co-management of RA. 1. Stoyanov et al. JMIR Mhealth Uhealth. 2015;3(1):e27–9.


Disclosure: R. Grainger, None; H. Townsley, None; B. White, None; T. Langlotz, None; W. Taylor, None.

To cite this abstract in AMA style:

Grainger R, Townsley H, White B, Langlotz T, Taylor W. A Systematic Review of Smartphone Applications for Measuring and Recording Rheumatoid Arthritis Disease Activity [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/a-systematic-review-of-smartphone-applications-for-measuring-and-recording-rheumatoid-arthritis-disease-activity/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-systematic-review-of-smartphone-applications-for-measuring-and-recording-rheumatoid-arthritis-disease-activity/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology